Copenhagen: Novo Nordisk Said On Tuesday That It Had Bought A Factory In North Carolina That Would Assist In Manufacturing And Packaging Its New Once-Daily Pill For Treating Type 2 Diabetes. The Tablet Version Of Its Diabetes Drug, Known As Semaglutide, Is An Important Growth Prospect For The Danish Drugmaker, Which Faces Pressure On Prices From Competitors And U.S. Lawmakers, Who Have Been Critical Of Rising Drug Costs.
